Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8917106 | 1.00 | SLC5A1 (0.33) | SLC5A1EGFR | |
| SCHEMBL8422234 | 1.00 | SLC5A1 (0.33) | SLC5A1EGFR | |
| SCHEMBL8422235 | 0.81 | KDM4E (0.31) | — | |
| SCHEMBL890128 | 0.78 | — | — | |
| SCHEMBL890097 | 0.78 | — | — | |
| SCHEMBL756341 | 0.77 | — | — | |
| SCHEMBL1650778 | 0.77 | — | — | |
| SCHEMBL6998150 | 0.77 | — | — | |
| SCHEMBL3633924 | 0.77 | ALDH1A1 (0.37) | — | |
| SCHEMBL31073506 | 0.77 | ALDH1A1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377872-B2 | Non-structural protein-3 (NS-3) protease inhibitors; viricides | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| WO-2010099527-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20080267916-A1 | CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080267916-A1 | CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS | PRSS1, CTSC, PREP | SLC5A1 773/4885EGFR 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.